Background and ObjectiveHypogonadism and frailty may impact postoperative outcomes for men undergoing radical nephrectomy (RN). We aimed to determine the prevalence of hypogonadism in men undergoing RN and whether hypogonadism and frailty are associated with adverse postoperative outcomes.MethodsWe identified men undergoing RN between 2012 and 2021 using the IBM Marketscan database. Frailty was determined using the Hospital Frailty Risk Score (HFRS). Patients were considered to have hypogonadism if diagnosed <5 years before RN. Length of stay (LOS), complications, emergency department (ED) visits, and readmissions were evaluated between men with and without hypogonadism at the time of surgery. Subgroup analysis of men with hypogonadism was performed to determine the effect of testosterone replacement therapy (TRT) on clinical outcomes.ResultsAmong 13 598 men who underwent RN, 972 (7.1%) had hypogonadism. Men with hypogonadism were more frail compared to men without hypogonadism (HFRS: median: 8.2, interquartile range [IQR]: 5.2–11.7 vs. median: 7.0, IQR: 4.3–10.7, p < 0.001) and had increased incidence of postoperative ileus (13.0% vs. 10.8%, p = 0.045), acute kidney injury (25.5% vs. 21.6% p = 0.005), and cardiac arrest (1.2% vs. 0.6%, p = 0.034). Hypogonadism was not associated with LOS, 90‐day ED visit or readmission. However, high‐risk frailty was associated with increased risk of 90‐day ED visit (hazard ratio [HR]: 2.1, 95% confidence interval [95% CI]: 1.9–2.4, p < 0.001) and 90‐day inpatient readmission (HR: 2.6, 95% CI: 2.2–3.1, p < 0.001), compared to low‐risk frailty patients. Among men with hypogonadism, TRT was not associated with any postoperative outcomes.ConclusionsHypogonadism and frailty should be considered in the preoperative evaluation for men undergoing RN as risk factors for adverse postoperative outcomes.